511-0000-00L  Drug Discovery and Development

SemesterHerbstsemester 2021
DozierendeJ. Hall, U. Thibaut, K.‑H. Altmann, M. Arand, J. Scheuermann, R. Schibli, H. U. Zeilhofer
Periodizitätjährlich wiederkehrende Veranstaltung
LehrspracheEnglisch
KommentarOnly for MSc Pharmaceutical Sciences.



Lehrveranstaltungen

NummerTitelUmfangDozierende
511-0000-00 GDrug Discovery and Development Für Fachstudierende und Hörer/-innen ist eine Spezialbewilligung der Dozierenden notwendig.
Two-day block course with group work.
14s Std.
24.11.10:15-17:00HG F 26.3 »
25.11.08:15-17:00HG F 26.3 »
U. Thibaut, J. Hall
535-0901-01 SFrom A to Z in Drug Discovery and Development I1 Std.
Mi/107:45-09:30HCI J 3 »
J. Hall, K.‑H. Altmann, M. Arand, J. Scheuermann, R. Schibli, H. U. Zeilhofer

Katalogdaten

KurzbeschreibungThis course provides an overview over the concepts and processes employed in today's drug discovery and development. It has an introductory character but will also provide more detailed insights employing real life examples. The course combines lectures and interactive elements with active participation of the students.
LernzielStudents
- Understand the drug discovery process and can explain major approaches and relevant technical terms (for details see lecture notes).
- Understand and appreciate the content and timing of drug development process steps, development phases and decision criteria.
- Understand the concepts underlying drug product development through all the phases from preclinical and clinical development to regulatory submission, approval and market launch.
- Can differentiate between small molecule drug development and biological drug development.
- Understand the most important differences between legal and regulatory requirements for drug development and approval for the major markets EU and USA.
InhaltCourse unit comprises weekly lectures covering the early phases of target and drug discovery (535-0901-01 S "From A to Z in Drug Discovery and Development I") with group work in the area of Drug Development (511-0000-00 G). Group work is 2 full days (Days 1 and 2) and comprises: introduction to the entire suite of drug product development processes in the pharmaceutical industry, covering: preclinical research and development, clinical development, regulatory processes and market launch.
R&D support processes such as project management, quality management, pharmacovigilance and pharmacoeconomics will be covered as well as organizational and governance aspects of the pharmaceutical industry. In addition, important success factors for a later career in the pharmaceutical industry will be discussed and highlighted at the end of the course.
SkriptWill be published on "mystudies"
LiteraturG. Nahler (Hrsg.) Dictionary of pharmaceutical medicine, Springer, Wien, 2013 (3rd edition)
Further readings will be listed in the lecture notes.
Voraussetzungen / BesonderesThis course provides the essential basic knowledge required for the industry-specific modules of the spring semester.

Safety conceptt: https://chab.ethz.ch/studium/bachelor1.html

Leistungskontrolle

Information zur Leistungskontrolle (gültig bis die Lerneinheit neu gelesen wird)
Leistungskontrolle als Semesterkurs
ECTS Kreditpunkte2 KP
PrüfendeJ. Hall, K.-H. Altmann, M. Arand, J. Scheuermann, R. Schibli, U. Thibaut, H. U. Zeilhofer
Formunbenotete Semesterleistung
PrüfungsspracheEnglisch
RepetitionRepetition ohne erneute Belegung der Lerneinheit möglich.
ZulassungsbedingungStudents have fully attended the weekly lecture course 535-0901-01 S (From A to Z in Drug Discovery and Development I) and Group Work days 1 and 2.
Zusatzinformation zum PrüfungsmodusOnline examination and active oral participation during lectures and group work.
Digitale PrüfungDie Prüfung findet auf Geräten statt, die von der ETH Zürich zur Verfügung gestellt werden.

Lernmaterialien

Keine öffentlichen Lernmaterialien verfügbar.
Es werden nur die öffentlichen Lernmaterialien aufgeführt.

Gruppen

Keine Informationen zu Gruppen vorhanden.

Einschränkungen

Allgemein : Für Fachstudierende und Hörer/-innen ist eine Spezialbewilligung der Dozierenden notwendig
VorrangDie Belegung der Lerneinheit ist nur durch die primäre Zielgruppe möglich
Primäre ZielgruppePharmaceutical Sciences MSc (512000)

Angeboten in

StudiengangBereichTyp
Pharmaceutical Sciences MasterKernfächer IOInformation